Investor Overview

Corporate Profile

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is a patient-focused, innovative, commercial-stage, global biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and product candidates. We have also built an in-house team with strong product discovery and translational research capabilities and are establishing a pipeline of proprietary product candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor & Media Contacts

Zai Lab
Ron Aldridge, Executive Director, Investor Relations
+1 (781) 434-8465
ronald.aldridge@zailaboratory.com

Lina Zhang, Executive Director, Investor Relations and Capital Market
+86 136 8257 6943
lina.zhang@zailaboratory.com

Media Inquiries
Danielle Halstrom, SVP, Global Head of Communications
+1 (215) 280-3898 
danielle.halstrom@zailaboratory.com 
 
Xiaoyu Chen, Senior Director, Corporate Communications
+86 185 0015 5011
xiaoyu.chen@zailaboratory.com
 

Investor Inquiries
Pete Rahmer
415-515-9763
prahmer@enduranceadvisors.com